Daniil Libman
Family · Morristown, NJNPI 1669924965
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 674 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 33 manufacturers reported payments, led by AbbVie at 27.3% of the total. 2025 is the largest year on record at $3,961, 4.6 times the $864 reported in 2021. Among family clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 674 payments — averaging $16.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
- Aimmune Therapeutics, Inc.$660
- QOL Medical, LLC$657
- Pfizer$586
- Takeda Pharmaceuticals U.S.A., Inc.$513
- plus $4K from 27 others
What the payments were for
- Food & beverage$11,188100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 204 | $3,058 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 127 | $1,595 |
| Aimmune Therapeutics, Inc. | 35 | $660 |
| QOL Medical, LLC | 27 | $657 |
| Pfizer | 32 | $586 |
| Takeda Pharmaceuticals U.S.A., Inc. | 25 | $513 |
| Johnson & Johnson | 37 | $452 |
| Madrigal Pharmaceuticals | 14 | $392 |
| Intercept Pharmaceuticals, Inc. | 15 | $355 |
| Braintree Laboratories, Inc. | 14 | $299 |
| Ironwood Pharmaceuticals, Inc | 17 | $280 |
| Ardelyx, Inc. | 17 | $264 |
| Nestle Healthcare Nutrition Inc. | 19 | $249 |
| Ipsen Biopharmaceuticals, Inc | 6 | $212 |
| Vivus LLC | 12 | $210 |
| Ferring Pharmaceuticals Inc. | 11 | $210 |
| Lilly USA, LLC | 11 | $199 |
| Celltrion USA Inc. | 9 | $162 |
| Janssen Scientific Affairs, LLC | 1 | $127 |
| Sanofi | 6 | $115 |
| Gilead | 6 | $110 |
| Evoke Pharma, Inc. | 5 | $87 |
| Regeneron Healthcare Solutions, Inc. | 4 | $67 |
| Phathom Pharmaceuticals, Inc. | 4 | $64 |
| Orphalan Inc | 4 | $62 |
| Biocon Biologics Inc | 2 | $46 |
| Boston Scientific | 2 | $42 |
| Bristol Myers Squibb | 3 | $42 |
| Blueprint Medicines Corporation | 1 | $24 |
| Merck | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Novo Nordisk | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,203 in reported general payments places this provider in the 95th percentile of 2,692 family providers in New Jersey.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 82 | $292,349 |
| RinvoqUpadacitinib | 14 | $106,663 |
| ZenpepLipase/Protease/Amylase | 20 | $51,761 |
| LinzessLinaclotide | 50 | $34,809 |
| IbsrelaTenapanor Hcl | 18 | $30,302 |
| OzempicSemaglutide | 20 | $18,575 |
| Mesalamine | 32 | $9,809 |
| Sucralfate | 36 | $6,614 |
| Lubiprostone | 55 | $6,402 |
| MotegrityPrucalopride Succinate | 11 | $5,648 |
| Pantoprazole Sodium | 455 | $5,030 |
| CholestyramineCholestyramine (With Sugar) | 39 | $2,207 |
| Famotidine | 180 | $1,881 |
| Omeprazole | 52 | $974 |
| Ursodiol | 15 | $873 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Rinvoq, Linzess | $3,058 | $433,820146 claims |
| Aimmune Therapeutics, Inc.Zenpep | $660 | $51,76120 claims |
| Ardelyx, Inc.Ibsrela | $264 | $30,30218 claims |
| Novo NordiskOzempic | $15 | $18,57520 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $513 | $5,64811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,692 family providers in New Jersey.
Other family in Morristown
- Jennifer DemaioMorristown$412K
- Megan FiloramoMorristown$53K
- Brittany LautherMorristown$20K
- Jenessa DieterleMorristown$15K
- Kara TrlicaCranbury$186K
- Nicole BauerParamus$161K
- China BattistaWall Township$142K
- Nancy EisenbergerVoorhees$82K
- Jennifer AbitabiloGlen Ridge$54K
- Shawn DenningToms River$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.